for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

J B Chemicals and Pharmaceuticals Ltd

JBCH.NS

Latest Trade

361.70INR

Change

4.05(+1.13%)

Volume

9,132

Today's Range

359.05

 - 

364.00

52 Week Range

272.30

 - 

411.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
357.65
Open
360.00
Volume
9,132
3M AVG Volume
1.63
Today's High
364.00
Today's Low
359.05
52 Week High
411.00
52 Week Low
272.30
Shares Out (MIL)
80.24
Market Cap (MIL)
28,568.26
Forward P/E
12.54
Dividend (Yield %)
1.40

Next Event

Q2 2020 J B Chemicals and Pharmaceuticals Ltd Earnings Release

Latest Developments

More

India's J B Chemicals And Pharmaceuticals June-Qtr Consol Net Profit Rises

India's J B Chemicals And Pharmaceuticals March Qtr Net PAT Rises

India's J B Chemicals And Pharmaceuticals Dec Qtr Net PAT Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About J B Chemicals and Pharmaceuticals Ltd

J. B. Chemicals & Pharmaceuticals Limited is a pharmaceutical company. The Company manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs). The Company's business segments include domestic formulation business, exports and API business. The Company markets various contrast media products in India, such as Contrapaque (Iohexol), Lek Pamidol (Iopamidol), Trazograf (Diatrazoic acid), Trazogastro - Oral contrast (Diatrazoic acid), Magnilek Injection (Gadopentatic acid) and Cardiolek Injection (Iodixanol). The Company's brands for the Indian pharmaceutical market include Metrogyl (Metronidazole), Nicardia (Nifedipine), Rantac (Ranitidine), Dicloran (Diclofenac Sodium), OF (Ofloxacin), Cilacar (Cilnidipine) and Zecuf herbal. It manufactures generic products for the regulated markets and branded formulations for the emerging markets. It manufactures various APIs, such as Cilnidipine, Diclofenac Acid and Gadopentatic acid.

Industry

Biotechnology & Drugs

Contact Info

Neelam Centre, 4th Floor

B Wing, Hind Cycle Road

Worli

+91.22.24395200

http://www.jbcpl.com/

Executive Leadership

Jyotindra B. Mody

Executive Chairman of the Board, Managing Director

Pranabh D. Mody

President, Whole-Time Director - Operations, Director

Mayur C. Mehta

Compliance Officer, Company Secretary, General Manager

Bharat P. Mehta

Whole-Time Director - Planning & Development, Director

Shirish B. Mody

Whole-Time Director - Marketing, Director

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

13.7K

2018

14.1K

2019

16.4K

2020(E)

18.0K
EPS (INR)

2017

21.420

2018

16.520

2019

23.540

2020(E)

28.403
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's JB Chemicals & Pharma Dec Qtr Profit Falls

* DEC QUARTER NET PROFIT 338.5 MILLION RUPEES VERSUS 357.6 MILLION RUPEES YEAR AGO

BRIEF-J B Chemicals And Pharmaceuticals Gets EU Approval For Mfg Facilities At Panoli

* SAYS EU APPROVAL FOR MANUFACTURING FACILITIES AT PANOLI Source text for Eikon: Further company coverage:

BRIEF-J B Chemicals & Pharma Gets U.S. FDA Nod For Supplementary ANDA For Atenolol Tablets

* SAYS CO GETS SUPPLEMENTARY ANDA APPROVAL BY US FDA FOR ATENOLOL TABLETS

BRIEF-India's JB Chemicals & Pharma Sept-qtr profit rises

* Sept quarter pat 517.2 million rupees versus 452 million rupees year ago

BRIEF-India's J B Chemicals and Pharmaceuticals March-qtr profit falls

* March quarter net profit 421.5 million rupees versus profit 505.4 million rupees year ago

BRIEF-J B Chemicals and Pharmaceuticals Dec qtr profit falls

* Dec quarter net profit 357.6 million rupees versus profit 468.8 million rupees year ago

BRIEF-J B Chemicals and Pharmaceuticals Sept qtr profit after tax rises

* J B Chemicals and Pharmaceuticals Ltd - sept quarter net profit after tax 452 million rupees versus profit after tax 421.5 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up